DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Fingolimod
Fingolimod
The Change of Fingolimod Patient Profiles Over Time
Download
Medical Review(S) Clinical Review
Analysis of Changes in Disease Modifying Treatment in The
Patient Focused Disease State and Assistance Programs
COMPARISON of the WHO ATC CLASSIFICATION & Ephmra/Intellus Worldwide ANATOMICAL CLASSIFICATION
The Real-World Patient Experience of Fingolimod and Dimethyl Fumarate
Fingolimod (Gilenya)
CIRCULAR 73 of 2015: Entry and Verification (E&V) Criteria for Identifying Beneficiaries with Risk Factors in Medical Scheme
(Fingolimod) for Multiple Sclerosis Multiple Sclerosis Pg 843 Silent Stroke Risk Could Rise with Hypertension Pg 844
Tysabri® (Natalizumab)
Analysis of Biological Treatments in Patients with Multiple Sclerosis in Estonia
Siponimod—A Selective Sphingosine-1-Phosphate Modulator for Secondary Progressive Multiple Sclerosis
Cost-Effectiveness of Cladribine Tablets and Fingolimod in the Treatment of Relapsing Multiple Sclerosis with High Disease Activity in Spain
Ozanimod to Treat Relapsing Forms of Multiple Sclerosis: a Comprehensive Review of Disease, Drug Efficacy and Side Effects
Benefit–Risk Profile of Sphingosine-1-Phosphate
GILENYA® Cardiac Arrhythmias Requiring Anti-Arrhythmic Treatment with Class Ia Or Safely and Effectively
Lemtrada (Alemtuzumab)
Top View
Fingolimod-Associated Macular Edema (FAME) in the Treatment of Multiple Sclerosis I. Case History • Patient Demographics: O 61
Gaining First Insights on Secondary Progressive Multiple Sclerosis Patients Treated with Siponimod in Clinical Routine: Protocol of the Noninterventional Study AMASIA
Estonian Statistics on Medicines 2013 1/44
Gilenya (Fingolimod) Aubagio (Teriflunomide) Tecfidera (BG-12)
Analyses of Spontaneous Adverse Drug Reaction Databases Using Descriptive and Inferential Statistics
Celgene Bets Big on Scripps-Originated Autoimmunity Candidate
Tysabri® (Natalizumab Injection for Intravenous Use – Biogen)
Real World Comparison of Patient Multiple Adherence and Persistence to Sclerosis Fingolimod Vs
ALEMTUZUMAB/FINGOLIMOD/NATALIZUMAB for Multiple Sclerosis
The Development of Fingolimod (FTY720, Gilenya)
Cladribine Tablets
Fingolimod for the Treatment of Multiple Sclerosis: a Review of the Evidence from the FREEDOMS and TRANSFORMS Studies
Sphingosine-1-Phosphate Receptor Modulators in Multiple Sclerosis
Ozanimod 0.5 Mg Or 1 Mg Ozanimod Daily, Or Weekly Injections of Interferon Beta-1A
Multiple Sclerosis, Disease-Modifying Therapies and COVID-19: a Systematic Review on Immune Response and Vaccination Recommendations
Multiple Sclerosis Agents Aubagio® (Teriflunomide) Gilenya® (Fingolimod) Mayzent® (Siponimod) Tecfidera® (Dimethyl Fumarate) Zeposia® (Ozanimod) Effective 01/01/2021
View Transcript
Cutaneous Side Effects of First / Second Line Oral Disease - Modifying Treatments in Patients with Multiple Sclerosis
O-Cyclic Phytosphingosine-1-Phosphate
Switch Analysis of Teriflunomide from Other Multiple Sclerosis Disease Modifying Therapies Ronald O
Siponimod Enriches Regulatory T and B Lymphocytes in Secondary Progressive Multiple Sclerosis
Ponesimod / ACT-128800 Chronic Graft Versus Host Disease Protocol AC-058C202
Machine Learning-Based Prediction and Characterization of Drug-Drug
8/15/2020 Code(S): HCPCS J2323 SUBJECT: Tysabri (Natalizumab)
The Neuroprotective Action of Lenalidomide on Rotenone Model Of
GILENYA(Fingolimod)
Summary Review
Important Things to Remember About Gilenya® (Fingolimod) Treatment for Patients, Parents and Caregivers
The Legally Binding Text Is the Original French Version TRANSPARENCY
Crystalline Forms of Fingolimod Hcl Kristalline Formen Von Fingolimod Hcl Formes Crystallines De Fingolimod Hcl
Assessment Report
Hematological Alterations Related to Treatment with Teriflunomide And
Tysabri® (Natalizumab) Injection
209899Orig1s000
Impact of Fingolimod on Multiple Sclerosis
FDA Approves First Drug to Improve Walking in MS Patients
A Report on Comparative Safety and Efficacy of Ponesimod in the Treatment of Multiple Sclerosis (MS)
Sphingosine 1-Phosphate Receptor Modulation Suppresses Pathogenic Astrocyte Activation and Chronic Progressive CNS Inflammation
Cyclical and Dose-Dependent Responses of Adult Human Mature Oligodendrocytes to Fingolimod
List of Selected Drugs
Guidelines for ATC Classification and DDD Assignment 2021
Effect of Ozanimod (RPC1063) on Action Potential Parameters in Adult Human Purkinje Fib Ers Short Title: Ozanimod on Purkinje F
Tysabri® (Natalizumab) Injection
Outcomes After Fingolimod to Alemtuzumab Treatment Shift In
Sphingosine-1-Phosphate Receptor Modulators and Oligodendroglial Cells: Beyond Immunomodulation
Oral Ponesimod in Relapsing–Remitting Multiple Sclerosis: A
Alemtuzumab Is a Budget-Saving Alternative to Fingolimod And
Effect of FTY720 (Fingolimod) on Graft Survival in Renal Transplant Recipients
Ozanimod in Multiple Sclerosis
Relapsing Remitting Multiple Sclerosis: Treatment Update Outline
Short Term Relapse Risk After Switching from Fingolimod To
Access Plans High Risk Prescription List
Treatment with Alemtuzumab Or Rituximab After Fingolimod Withdrawal in Relapsing–Remitting Multiple Sclerosis Is Effective and Safe
Cladribine/Fingolimod/Natalizumab for Multiple Sclerosis Special
Tenofovir Alafenamide
Immunosuppressants DISCLOSURE STATEMENT Speaker: James C
PHARMACOLOGY REVIEW(S) Tertiary Pharmacology Review
Novartis Letter
MS Progress Notes... a Newsletter for Health Professionals Volume 9, Number 2 Spring 2014
A New Oral Medication for MS Is Approved by FDA!!
Emerging Therapies for Multiple Sclerosis
213498Orig1s000